Celcuity's breast cancer win; Odyssey plans $205M IPO

May 4, 2026 10:54 AM EDT News Briefing Cel­cu­ity breast can­cer win; Odyssey plans $205M IPO; La­tus Bio ex­tends Se­ries A ENDPOINTS Cel­cu­ity’s breast can­cer drug wins again: The com­pa­ny said two reg­i­mens with its ex­per­i­men­tal drug geda­tolis­ib suc­ceed­ed in PIK3CA mu­tant … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER